Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
International Journal of Molecular Sciences|June 26, 2026
Longitudinal Analysis of HIV-2 Proviral DNA Reveals Archived Protease Inhibitor Resistance and Reservoir Evolution over Eight YearsPaloma Gonçalves, Inês Lopes, Andreia Martins, et al.Scientific Reports|August 5, 2020
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in SpainClaudia Palladino, Ifeanyi Jude Ezeonwumelu, Irene Mate-Cano, et al.Scientific Reports|August 18, 2018
Epidemic history of hepatitis C virus genotypes and subtypes in PortugalClaudia Palladino, Ifeanyi Jude Ezeonwumelu, Rute Marcelino, et al.Retrovirology|December 22, 2016
A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision supportMatthias Döring, Pedro Borrego, Joachim Büch, et al.Nanoscale|August 15, 2015
Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicidesVerónica Briz, Daniel Sepúlveda-Crespo, Ana Rita Diniz, et al.Antiviral Therapy|February 2, 2012
Baseline susceptibility of primary HIV-2 to entry inhibitorsPedro Borrego, Rita Calado, José M Marcelino, et al.Tumori|September 10, 2015
Exclusion criteria vs reality: dual BRAF/MEK inhibition and radiotherapy in a patient with melanoma metastatic to the brain and ECOG 3Iván Márquez-Rodas, Jose-Antonio Avilés-Izquierdo, Verónica Parra, et al.Microbiology Spectrum|November 29, 2022
Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected IndividualsFrancisco Martin, José Maria Marcelino, Claudia Palladino, et al.Journal of Clinical Microbiology|May 19, 2017
Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected PatientsPedro Borrego, Maria Fátima Gonçalves, Perpétua Gomes, et al.Retrovirology|October 26, 2013
Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody responseCheila Rocha, Rita Calado, Pedro Borrego, et al.Pageof 4